Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 108 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]
2. Cita con resumen
Day M. Italian expert questions need for expanded vaccination schedule. BMJ 2015;351:h6181. [Ref.ID 99693]
3. Cita con resumen
Anónimo. Drugs for the doctor's bag: 2-children. Drug Ther Bull 2015;53:69-72. [Ref.ID 99214]
4. Cita con resumen
Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath P, Lewis DJM, Pollard AJ, Turner DPJ, Bazaz R, Ganguli A, Havelock T, Neal KR, Ikike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MCJ, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123-31. [Ref.ID 98454]
5. Cita con resumen
Anónimo. Vaccines for travelers. Med Lett Drugs Ther 2014;56:115-20. [Ref.ID 98403]
6. Cita con resumen
Anónimo. (Bexsero) vaccin méningococcique B. Prescrire 2014;34:251-4. [Ref.ID 97432]
7. Cita con resumen
Martinón-Torres F. Immunisation against meningococcus B: the case of Spain. Lancet 2013;382:1552-3. [Ref.ID 96522]
8. Cita con resumen
Anónimo. Vaccin méningococcique conjugué A, C, W135, Y à apartir de l'âge de 2 ans. Prescrire 2013;33:176-7. [Ref.ID 95023]
9.Tiene citas relacionadas
Molyneux E, Nizami SQ, Saha S, Huu KT, Azam M, Bhuta ZA, Zaki R, Weber MW, Qazi SA, for the CSF 5 Study Group. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 2011;377:1837-45. [Ref.ID 90854]
10.Tiene citas relacionadas
Snape MD, Kelly DF. Fine with five? Shorter antibiotic courses for childhood meningitis. Lancet 2011;377:1809-10. [Ref.ID 90841]
12.Enlace a cita original
Visintin C, Mugglestone MA, Fields EJ, Jacklin P, Murphy MS, Pollard AJ, on behalf of the Guideline Development Group. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summay of NICE guidance. BMJ 2010;341:92-4. [Ref.ID 88874]
13.
Tan LKK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010;362:1511-20. [Ref.ID 88302]
14. Cita con resumen
Moloney A. Latin America faces hurdles in health research. Lancet 2009;374:1053-4. [Ref.ID 86847]
15. Cita con resumen
Platt R, Wilson M, Chan A, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network — Improving the evidence of medical-product safety . N Engl J Med 2009;361:645-7. [Ref.ID 86387]
16.Tiene citas relacionadas
17.Tiene citas relacionadas
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity of a tretavalent meningococcal glycoconjugate vaccine in infants. A randomized controlled trial. JAMA 2008;299:173-84. [Ref.ID 82008]
19.Tiene citas relacionadas
Gardner P. Prevention of meningococcal disease. The author replies. N Engl J Med 2007;356:525-6. [Ref.ID 79087]
20.Tiene citas relacionadas
Senanayake SN. Prevention of meningococcal disease. N Engl J Med 2007;356:525. [Ref.ID 79086]
Seleccionar todas
 
 1 a 20 de 108 siguiente >>